- Molecular NameUrsodeoxycholic acid
- Synonym(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3,7-Dihydroxycholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid; Acide ursodesoxycholique [inn-french]; Acido ursodeossicolico [italian]; Acido ursodeoxicolico [inn-spanish]; Acidum ursodeoxycholicum [inn-latin]; Chenodeoxycholic acid; Iso-ursodeoxycholic acid; UDCS; Ursodesoxycholic acid; Ursodiol
- Weight392.58
- Drugbank_IDDB01586
- ACS_NO128-13-2
- Show 3D model
- LogP (experiment)3.0
- LogP (predicted, AB/LogP v2.0)3.39
- pkaN/A
- LogD (pH=7, predicted)1.29
- Solubility (experiment)0.0201 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.99
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors3
- No.of HBond Acceptors4
- No.of Rotatable Bonds4
- TPSA77.76
- StatusFDA approved
- AdministrationN/A
- PharmacologyThe drug reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability38.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityNeither accidental nor intentional overdosing with ursodeoxycholic acid has been reported. Doses of ursodeoxycholic acid in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD50 for ursodeoxycholic acid in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with ursodeoxycholic acid would probably be diarrhea, which should be treated symptomatically.
- LD50 (rat)N/A
- LD50 (mouse)N/A